Study (year) | Setting | LB/TPAI | AN | Treatment group | Control group | Follow-up | PA | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
No. | Age | Male | Female | BMI | |||||||
Bramlett 2012 [23] | USA | 25/34 | 61.1/62.2 | 13/11 | 12/23 | 31.2/31.5 | GA | LB 266 mg | Bup 150 mg | 36 days | Y |
Schroer 2015 [24] | USA | 58/53 | 67/68.6 | 24/21 | 34/32 | 32/32 | SA/GA | LB 266 mg, Bup 75 mg | Bup 150 mg | 3 weeks | Y |
Collis 2016 [25] | USA | 54/51 | 63.7/63.5 | 25/14 | 29/37 | 34.1/35.7 | GA | LB 266 mg | Rop 246.25 mg, Epi 0.5 mg, Ket 30 mg, Clo 0.08 mg | 8 weeks | N |
Jain 2016 [26] | USA | 63/62 | 68.3/67.5 | 19/17 | 44/45 | 33.3/33.3 | SA | LB 266 mg | Bup 75 mg, Epi 0.15 mg, Mor 10 mg | NM | Y |
Schwarzkopf 2016 [27] | USA | 20/18 | 63/59 | 7/10 | 13/8 | 29.3/29.5 | SA | LB 266 mg, Bup 50 mg | Rop 246.25 mg, Epi 0.5 mg, Clo 80 mg, Tor 30 mg | NM | Y |
Snyder 2016 [28] | USA | 35/35 | 67.3/65.6 | 22/15 | 13/20 | 30.68/31.29 | SA/GA | LB 266 mg | Rop 400 mg, Epi 0.6 mg, Ket 30 mg, Mor 5 mg | 10 days | N |
Alijanipour 2017 [29] | USA | 59/59 | 64.3/64.9 | 29/27 | 30/32 | 32.3/28.7 | SA | LB 266 mg, Epi 0.5 mg | Bup 50 mg, Epi 0.1 mg | 6 weeks | Y |
Declaire 2017 [30] | USA | 47/49 | 69.7/67.7 | 21/21 | 26/28 | 31.5/31.9 | SA/GA | LB 266 mg, Bup, Epi, Ket, Mor | Rop, Epi, Ket, Mor | NM | Y |
Mont 2017 [15] | USA | 70/69 | 66/66 | 27/30 | 43/39 | 32.4/31.3 | SA | LB 266 mg, Bup 100 mg | Bup 100 mg | NM | Y |
Smith 2017 [31] | USA | 104/96 | 66/66 | 54/28 | 50/68 | 31.5/31.6 | SA | LB 266 mg | Bup | 6 weeks | N |
Danoff 2018 [32] | USA | 29/29 | 62.9/62.9 | 15/15 | 14/14 | 30.4/30.4 | SA | LB 266 mg, Bup 75 mg | Rop 250 mg, Epi 0.5 mg, Ket 30 mg, Clo 0.08 mg | 6 weeks | Y |
Schumer 2018 [36] | USA | 66/64 | NM | NM | NM | NM | SA | LB 266 mg, Bup 1 mg/kg | Bup 150 mg | 6 weeks | N |
Suarez 2018 [33] | USA | 52/52 | 68.1/67.3 | 19/26 | 33/26 | 30.8/32.01 | SA | LB 266 mg, Bup 75 mg | Rop 246.25 mg, Epi 0.5 mg, Ket 30 mg, Clo 0.08 mg | 6 weeks | Y |
Zlotnicki 2018 [34] | USA | 38/40 | 63.2/64.3 | 19/14 | 19/26 | 35.5/35.4 | SA/GA | LB 266 mg | Bup 100 mg | NM | N |
Dysart 2019 [35] | USA | 70/69 | 66/66 | 29/28 | 41/41 | NM | SA | LB 266 mg, Bup 100 mg | Bup 100 mg | 24 h | N |
Hyland 2019 [19] | USA | 30/29 | 65.0/61.2 | 14/13 | 16/16 | NM | GA + ACB | LB 266 mg | Rop 40 mg, Ket 30 mg, Mor 10 mg, Methy 40 mg | NM | Y |